Rugiet Ready’s most commonly reported side effects are headache, facial flushing, nasal congestion, indigestion, nausea, dizziness and temporary vision changes such as blurring or a blue tint. The one absolute rule is this: never take Rugiet with a nitrate medication (nitroglycerin, isosorbide), with amyl nitrite “poppers”, or with a guanylate cyclase stimulator such as riociguat, because that combination can drop blood pressure to a life threatening level. Rugiet also carries risks that pure PDE5 products do not, because it contains apomorphine, and because the finished troche is a compounded 503A product that the FDA has never reviewed for safety, effectiveness or quality.
This page covers safety only. For what the product is and how it performs, see our Rugiet Ready review; for pricing, see our Rugiet cost breakdown; for the head to head against the closest compounded competitor, see Ro Sparks vs Rugiet Ready.
Safety critical: nitrates, poppers and riociguat
Do not take Rugiet Ready if you use nitrate medication in any form, recreational nitrite “poppers”, or a guanylate cyclase stimulator such as riociguat. This is not a caution. It is an absolute contraindication, and the consequence is a sudden, severe and potentially fatal fall in blood pressure.
This rule comes directly from the FDA approved labels for the two PDE5 drugs inside the troche. The VIAGRA (sildenafil) label states that sildenafil “was shown to potentiate the hypotensive effects of nitrates, and its administration to patients who are using nitric oxide donors such as organic nitrates or organic nitrites in any form either regularly and/or intermittently is therefore contraindicated.” The same label states: “Do not use VIAGRA in patients who are using a GC stimulator, such as riociguat. PDE5 inhibitors, including VIAGRA, may potentiate the hypotensive effects of GC stimulators.” The CIALIS (tadalafil) label independently lists nitrates and riociguat as contraindications.
Two details that people get wrong:
- The bar lasts far longer than one evening. Because Rugiet contains tadalafil, the long acting PDE5 inhibitor, the CIALIS label’s guidance applies: “At least 48 hours should elapse after the last dose of CIALIS before nitrate administration is considered,” and then only in a life threatening situation under medical supervision. A dose taken Friday can still matter on Sunday.
- “Poppers” count. Amyl and butyl nitrite are nitric oxide donors. Rugiet’s own safety documentation names poppers explicitly. Recreational use does not exempt them.
If you take nitrates for chest pain, or you are prescribed riociguat, Rugiet is not a product to negotiate around. Tell any emergency clinician that you have taken a sildenafil and tadalafil containing product, because it changes what they can safely give you.
What are the common side effects of Rugiet, and what should you do about them?
The effects below are the ones consistently reported for Rugiet’s ingredients and listed in Rugiet’s own safety information. No frequency data exists for this specific troche, because the combination has never been through a clinical trial. The percentages in the middle column come from the FDA approved labels of the single active products and are shown only as a reference point for the individual molecules, not as the rate you should expect from Rugiet.
| Effect | Reported frequency in approved single-active labels | What to do |
|---|---|---|
| Headache | Sildenafil 21 to 28 percent; tadalafil 5 to 15 percent | Usually mild and self limiting. Persistent or severe headache warrants a call to your prescriber. |
| Facial flushing | Sildenafil 18 to 19 percent; tadalafil 1 to 3 percent | Expected and harmless. Worsened by alcohol. |
| Nasal congestion | Sildenafil 4 to 9 percent; tadalafil 1 to 3 percent | No action needed. Avoid stacking decongestants without asking a clinician. |
| Indigestion or reflux | Sildenafil 9 to 17 percent; tadalafil 1 to 10 percent | Common. Discuss with your prescriber if it recurs every dose. |
| Nausea | Apomorphine specific. Sublingual apomorphine ED trials reported nausea as the most common treatment related effect, dose related | Report it. Nausea is the apomorphine signal, and it is dose dependent, so a prescriber may adjust. |
| Dizziness or lightheadedness | Reported for both PDE5 inhibitors and for sublingual apomorphine in ED trials | Sit or lie down. Recurrent dizziness suggests a blood pressure effect and needs clinical review. |
| Vision changes (blurring, blue tint, light sensitivity) | Sildenafil 2 to 11 percent, dose related | Usually transient. Sudden loss of vision is different, see below. |
| Back pain or muscle aches | Tadalafil 3 to 6 percent (back pain), 1 to 4 percent (myalgia) | Typically appears 12 to 24 hours after dosing and resolves on its own. |
| Sudden vision loss in one or both eyes | Rare, no reliable incidence figure | Stop the medication and seek medical attention immediately, per the PDE5 class labels. |
| Sudden decrease or loss of hearing | Rare, no reliable incidence figure | Stop the medication and seek prompt medical attention, per the PDE5 class labels. |
| Erection lasting more than four hours (priapism) | Rare | Medical emergency. Go to an emergency department. Untreated priapism can cause permanent tissue damage and loss of erectile function. |
| Fainting or near fainting | Uncommon but documented for sublingual apomorphine | Stop and seek medical evaluation before taking another dose. |
What does apomorphine add that pure PDE5 products do not carry?
Apomorphine is a dopamine agonist that acts centrally, in the brain, rather than on penile blood flow, and it brings a different class of adverse effects: nausea and vomiting, blood pressure drops on standing, and drowsiness. It is the single biggest reason Rugiet’s safety profile cannot be read off a Viagra label.
Has apomorphine ever been approved for erectile dysfunction in the United States?
No. Apomorphine has never been FDA approved for ED in the US. It is approved for Parkinson’s disease, as the subcutaneous injection APOKYN and in other Parkinson’s formulations. A sublingual apomorphine ED product, Uprima, was developed in the late 1990s, but TAP Pharmaceuticals withdrew the US new drug application in 2000. Contemporaneous reporting and a Public Citizen petition to the FDA attribute the concerns to hypotension and syncope observed during review. The product was later marketed in parts of Europe and is not a mainstream ED therapy today.
What is actually documented about apomorphine’s side effects at ED-relevant doses?
The published sublingual apomorphine ED trials give the most relevant picture, because they used sublingual delivery at ED-scale doses rather than Parkinson’s dosing. A European multicenter tolerability study using forced escalation from 2 mg to 4 mg reported nausea in 9.8 percent of treated patients versus 0.4 percent on placebo, dizziness in 7.1 percent versus 2.4 percent, and headache in 6.7 percent versus 4.0 percent (Von Keitz et al., BJU International, 2002, PMID 11872034). A pooled cross study analysis of phase II and III sublingual apomorphine trials reported nausea as the most common treatment related event at 11.7 percent, clearly dose related and diminishing with repeat dosing, with syncope reported in about 0.1 percent of patients under a dose optimization regimen.
Do the Parkinson’s disease figures apply to Rugiet?
No, and we will not extrapolate them. The APOKYN label reports somnolence in 35 percent of patients, nausea or vomiting in 30 percent, dizziness or postural hypotension in 20 percent, falls in 30 percent and hallucinations in 14 percent, and it warns about sudden onset of sleep, dose related QT prolongation and impulse control disorders. Those figures come from a subcutaneous injection given repeatedly through the day in people with advanced neurological disease. The route, dose and population are all different from an occasional sublingual ED troche, so quoting them as Rugiet’s risk would be misleading in the opposite direction.
What does transfer is the mechanism, and therefore the direction of risk: nausea, orthostatic blood pressure drops, sedation and, as a dopamine agonist class effect, impulse control changes. Rugiet’s own safety page acknowledges the impulse control and compulsive behavior risk.
The apomorphine interaction most people have never heard of
Apomorphine is contraindicated with 5-HT3 antagonist anti-nausea drugs, including ondansetron (Zofran), granisetron, dolasetron, palonosetron and alosetron. The APOKYN label describes “profound hypotension and loss of consciousness” with this combination. Rugiet lists the same contraindication. This matters practically, because ondansetron is exactly the drug someone might reach for to manage nausea, and because it is widely prescribed after surgery, for migraine and for chemotherapy.
How much apomorphine is in a Rugiet troche?
Rugiet does not publish the milligram amounts of any of its three actives on its public product pages, and describes dosing as personalized by the prescribing physician. For context, a competing compounded product, BlueChew’s GOLD chewable, does publish its composition and lists apomorphine at 2 mg, 3 mg or 4 mg depending on strength, alongside sildenafil, tadalafil and oxytocin. That is the same dose band studied in the sublingual apomorphine ED trials. We are not assuming Rugiet matches it. If you are prescribed Rugiet, ask for the exact apomorphine content in writing, because it is the number that determines your nausea and hypotension exposure.
Is combining sildenafil and tadalafil in one dose safe?
Nobody knows, because it has not been studied, and both manufacturers say so on their labels. The CIALIS label states: “The safety and efficacy of combinations of CIALIS and other PDE5 inhibitors or treatments for erectile dysfunction have not been studied.” The VIAGRA label carries a materially identical statement. Stacking two PDE5 inhibitors is not standard approved practice in erectile dysfunction.
The mechanistic concern is additive vasodilation, meaning a larger blood pressure drop than either drug alone, particularly for men also taking alpha blockers, other antihypertensives or alcohol. Adding apomorphine, which independently lowers standing blood pressure, stacks a third hypotensive mechanism onto the first two. There is no trial quantifying that three way effect. We are not going to invent a number for it, and neither should anyone else.
What does “compounded” mean for Rugiet’s safety evidence?
It means the finished product has had no FDA review at all. The FDA’s own position is unambiguous: “compounded drugs pose a higher risk to patients than FDA-approved drugs because compounded drugs do not undergo FDA premarket review for safety, effectiveness or quality.” Rugiet states the same thing on its product page.
Under Section 503A, compounding pharmacies are largely overseen by state boards of pharmacy rather than by the FDA, are not required to follow current Good Manufacturing Practice requirements in the way registered drug manufacturers are, and are generally not FDA registered or routinely FDA inspected. Sildenafil and tadalafil individually have decades of post-approval safety data, but that record belongs to the approved single-active tablets, not to a three-drug compounded troche made at a pharmacy scale facility. Conflating the two is the most common error in ED marketing, and it is the error this page exists to correct.
Rugiet versus the alternatives on regulatory exposure
| Product | Active ingredients | Finished product FDA approved? | Contains apomorphine? |
|---|---|---|---|
| Rugiet Ready | Sildenafil, tadalafil, apomorphine | No, compounded under 503A | Yes |
| BlueChew GOLD | Sildenafil, tadalafil, apomorphine, oxytocin | No, compounded | Yes |
| Ro Sparks | Sildenafil, tadalafil | No, compounded under 503A | No |
| Generic sildenafil (Viagra) | Sildenafil | Yes | No |
| Generic tadalafil (Cialis) | Tadalafil | Yes | No |
Rugiet Ready and BlueChew GOLD are the only two products in that table that carry apomorphine, and the differences between them go beyond regulatory status. Our Rugiet vs BlueChew comparison covers per-dose cost, full ingredient lists and the apomorphine question side by side.
Who should not take Rugiet without an in-person evaluation?
Anyone with a cardiac history should be evaluated in person rather than through an asynchronous online questionnaire. Sexual activity itself carries cardiac risk, and every mechanism in this troche lowers blood pressure. The categories that warrant an in-person workup, and a conversation with your own clinician rather than a telehealth form, include:
- Coronary artery disease, prior heart attack, arrhythmia or heart failure
- Any use of nitrates, nitrites or riociguat, which is disqualifying outright
- Low blood pressure, or a history of fainting or orthostatic symptoms
- Multiple antihypertensives or alpha blocker therapy
- Regular use of 5-HT3 antagonist anti-nausea drugs
- A prior episode of priapism, sickle cell disease, multiple myeloma or leukemia
- Prior non-arteritic anterior ischemic optic neuropathy, or retinitis pigmentosa
- Significant liver or kidney impairment
- A history of impulse control problems, gambling or compulsive behaviour, given the dopamine agonist component
This is not medical advice and it is not a screening tool. It is a list of reasons to talk to a physician who can examine you.
Has the FDA taken any action against Rugiet?
As of 2 August 2026, we found no FDA warning letter, safety communication, recall or medication health fraud notification naming Rugiet or Rugiet Ready. We searched the FDA warning letter database and fda.gov and found nothing. Absence of a warning letter is not a safety endorsement, and it is certainly not FDA approval.
The FDA has been active in this exact category, however. On 9 September 2025 the FDA issued a warning letter to Dermacare LLC, doing business as BlueChew, finding that claims about its compounded sildenafil and tadalafil products were false or misleading and that the products were misbranded, specifically because marketing implied equivalence to FDA approved products. That letter was part of a wave of letters targeting compounded drug advertising. Anyone evaluating a compounded ED product should read “same active ingredient as Viagra” style claims with that enforcement history in mind.
Our verdict on Rugiet’s safety
Rugiet Ready is a reasonable option for a healthy man with no cardiovascular disease, no nitrate or riociguat use, no 5-HT3 antagonist use, and a clear preference for the central arousal effect apomorphine is intended to provide, who has had that conversation with a prescriber who knows his full medication list. It is a poor choice for anyone with cardiac history, blood pressure instability, a fainting history, or a preference for products with actual outcome data behind them.
Our criteria, stated plainly. Ingredient-level evidence: strong for sildenafil and tadalafil, moderate and dated for sublingual apomorphine, non-existent for the three in combination. Finished product evidence: none. Regulatory oversight: state pharmacy board level, not FDA premarket review. Disclosure quality: below average, because the milligram content of the actives is not published. On that scorecard, Rugiet’s added risk over a plain generic tadalafil prescription is real but manageable in a screened, healthy patient, and it is not manageable through an online form alone if you have a heart condition. If the apomorphine pathway is not the specific thing you want, an approved single-active generic gives you a better evidence base at a lower price. See our full Rugiet review for how that trade-off plays out on effectiveness.
Frequently Asked Questions
Is Rugiet safe?
Rugiet is generally tolerated by healthy men who are properly screened, but it is not FDA approved and its three drug combination has never been tested in a clinical trial. Its individual ingredients are well characterized: sildenafil and tadalafil have decades of approved use, while apomorphine is approved for Parkinson’s disease and was never approved for ED in the US. The honest answer is that it is likely tolerable for a healthy, screened man and genuinely unsafe for anyone using nitrates, poppers or riociguat.
What happens if I take Rugiet with nitrates?
Blood pressure can fall catastrophically, causing fainting, heart attack or death. This applies to prescription nitrates such as nitroglycerin and isosorbide, to recreational nitrite poppers, and to guanylate cyclase stimulators such as riociguat. The combination is an absolute contraindication on the FDA labels of both sildenafil and tadalafil, and because Rugiet contains tadalafil, the CIALIS label advises that at least 48 hours should elapse after a dose before nitrates are even considered. If you have taken both, seek emergency care immediately and tell the clinician exactly what you took.
Can I take Rugiet with blood pressure medication?
Possibly, but only under a prescriber’s supervision, and never with nitrates or riociguat, which are absolute contraindications regardless of anything else. PDE5 inhibitors add to the blood pressure lowering effect of antihypertensives and alpha blockers, and apomorphine independently lowers standing blood pressure, so three mechanisms are stacking. Bring your complete medication list, including anything taken occasionally, to the consultation.
What happens if I take Rugiet with Zofran or another anti-nausea drug?
Apomorphine is contraindicated with 5-HT3 antagonists including ondansetron (Zofran), granisetron, dolasetron, palonosetron and alosetron. The FDA label for apomorphine describes profound hypotension and loss of consciousness with this combination, and Rugiet lists the same contraindication. Because ondansetron is a natural choice for nausea, and nausea is apomorphine’s most common side effect, this is a trap worth knowing about before it happens.
How long do Rugiet side effects last?
Headache, flushing and nasal congestion typically track the drug’s presence in the body and fade within hours, while tadalafil related back pain and muscle ache often appear 12 to 24 hours after dosing and resolve on their own. Because tadalafil is long acting, some effects can persist noticeably longer than they would with sildenafil alone. Any effect that does not resolve, or any vision or hearing change, should be reported to a clinician rather than waited out.
Can I drink alcohol with Rugiet?
Alcohol and Rugiet both lower blood pressure, so combining them increases the risk of dizziness, orthostatic symptoms and fainting. The tadalafil label specifically flags that substantial alcohol consumption increases the risk of orthostatic symptoms, and the apomorphine label states that alcohol potentiates its hypotensive effect and advises avoiding alcohol. Rugiet’s own guidance is to limit alcohol. Heavy drinking alongside this product is the single easiest way to turn a tolerable side effect into an emergency room visit.
Does Rugiet cause nausea?
Nausea is the characteristic apomorphine effect and is the most common treatment related adverse event in the published sublingual apomorphine ED trials, where it was clearly dose related and tended to diminish with repeated dosing. Because Rugiet does not publish its apomorphine content, you cannot predict your own exposure from the trial data. If nausea occurs, report it to your prescriber rather than self treating with an over the counter or leftover prescription antiemetic, given the 5-HT3 antagonist contraindication.
Can I take Rugiet if I have heart disease?
Not without an in-person cardiac evaluation. Sexual activity carries its own cardiac demand, and this product combines three separate blood pressure lowering mechanisms with no combination safety data. An asynchronous online questionnaire is not an adequate substitute for a clinician who can examine you, review your medications and assess your exercise tolerance.
What should I do if I get an erection lasting more than four hours?
Go to an emergency department immediately. An erection lasting more than four hours is priapism, a medical emergency, and untreated priapism can cause permanent penile tissue damage and permanent loss of erectile function. Tell the treating clinician that you took a product containing both sildenafil and tadalafil, because it affects how they manage you.
Sources
- DailyMed, VIAGRA (sildenafil citrate) tablets, full prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae2079a2-f3a9-4739-9611-0742b71e4761 (accessed 2 August 2026)
- DailyMed, CIALIS (tadalafil) tablets, full prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bcd8f8ab-81a2-4891-83db-24a0b0e25895 (accessed 2 August 2026)
- DailyMed, APOKYN (apomorphine hydrochloride) injection, full prescribing information, label revised June 2022. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3235535d-9ef9-4657-8b2a-176a807d091c (accessed 2 August 2026)
- US FDA, Understanding the Risks of Compounded Drugs. https://www.fda.gov/drugs/human-drug-compounding/understanding-risks-compounded-drugs (accessed 2 August 2026)
- US FDA, Compounding and the FDA: Questions and Answers. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers (accessed 2 August 2026)
- US FDA, Warning Letter to Dermacare LLC dba BlueChew, reference 716698, issued 9 September 2025. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/dermacare-llc-dba-bluechew-716698-09092025 (accessed 2 August 2026)
- Von Keitz AT, Ströberg P, Bukofzer S, Mallard N, Hibberd M. A European multicentre study to evaluate the tolerability of apomorphine sublingual administered in a forced dose-escalation regimen in patients with erectile dysfunction. BJU International, 2002. PMID 11872034. https://pubmed.ncbi.nlm.nih.gov/11872034/ (accessed 2 August 2026)
- Adverse Events and Patient Tolerability of Apomorphine SL 2 and 3 mg: A Cross-Study Analysis of Phase II and III Studies. European Urology Supplements, 2002. https://www.eu-openscience.europeanurology.com/article/S1569-9056(02)00010-6/abstract (accessed 2 August 2026)
- Apomorphine SL (Uprima): a new treatment for the management of erectile dysfunction. PubMed, PMID 11477485. https://pubmed.ncbi.nlm.nih.gov/11477485/ (accessed 2 August 2026)
- Public Citizen, Letter Urging Rejection of Apomorphine (Uprima). https://www.citizen.org/article/letter-urging-rejection-of-apomorphine-uprima/ (accessed 2 August 2026)
- CBS News, Uprima Drug Pulled From FDA Review (contemporaneous reporting of the 2000 NDA withdrawal). https://www.cbsnews.com/news/uprima-drug-pulled-from-fda-review/ (accessed 2 August 2026)
- Rugiet, Important Safety Information: Rugiet Ready. https://www.rugiet.com/important-safety/rugiet-ready (accessed 2 August 2026)
- Rugiet, Rugiet Ready product page. https://www.rugiet.com/erectile-dysfunction/ready (accessed 2 August 2026)
- BlueChew, GOLD chewable tablets product page, cited for disclosed apomorphine content in a comparable compounded product. https://bluechew.com/gold (accessed 2 August 2026)
Health Disclaimer: BestMedsHub is not a healthcare provider, telehealth service, pharmacy, or medical organization. We do not prescribe medication, diagnose conditions, render medical opinions, or facilitate clinical consultations. All content is for general informational and comparison purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a qualified physician, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any treatment, medication, supplement, or health program. Never disregard professional medical advice or delay seeking it because of anything you have read on this site. If you think you may have a medical emergency, call your local emergency number immediately.
FDA & Prescription Medication Disclaimer: Prescription medications referenced on this page are available only through a licensed healthcare provider after a clinical evaluation, and may not be appropriate or safe for everyone. Any statements regarding dietary supplements, wellness products, or off-label uses have not been evaluated by the U.S. Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary and are not guaranteed. Always read the medication guide and consult your prescriber and pharmacist about side effects, contraindications, and drug interactions.
